News

A recap of 3 Kidney Compass podcast episodes recorded at ERA 2025, including summaries and preview clips.

HCPLive spoke with Bowles at SLEEP 2025 on the staggered schedule, referred to as 1/3/2/3, and how it impacts firefighters' sleep.

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

With so many new medications ostensibly filling the niche typically occupied by ACE/ARBs, are the medications practically useful in a changed treatment landscape?

At SLEEP 2025, Colvonen discussed RCT findings that showed VeNS significantly improved PTSD and insomnia symptoms, offering a scalable solution for patients awaiting 1-on-1 care.

If approved, mavorixafor will be the second FDA-approved treatment and the first oral medication for CN.

This interview with Peter Lio, MD, at RAD 2025 provides several insights into the topic of topical steroid withdrawal versus atopic dermatitis and what the distinction may be.

FDA approves the new therapy under the name Enflonsia, offering effective RSV prevention for infants during their first RSV season.

In this interview at RAD 2025, Peter Lio, MD, highlighted whether precision medicine is a possibility in the near future in the atopic dermatitis management space.

In this Q&A discussion, Glick highlights several important points about topical steroid withdrawal and atopic dermatitis.

Phase 3 trials show enlicitide decanoate significantly lowers LDL cholesterol, offering a promising oral treatment for hyperlipidemia and cardiovascular risk.

A recent meta-analysis reveals GLP-1 RAs significantly reduce adverse kidney outcomes, highlighting their potential in chronic kidney disease management.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

This study highlights rates among females with up to 6 years of upadacitinib use of major adverse cardiovascular events, VTE, and malignancy.

A recent study reveals how personality traits like neuroticism and extraversion influence bedtime procrastination in young adults, impacting sleep health.

Zulueta discussed Mount Sinai's incidental lung nodule program using AI tools to improve follow-up and recent findings from the program presented at ATS.

This Q&A interview features Jeff Yu, MD, in a discussion regarding his presentation on chronic hand eczema at the 2025 RAD Conference.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

These late-breaking data highlight the real-world efficacy of upadacitinib for patients with atopic dermatitis who are either bio-naïve or bio-experienced.

Califf discusses the difficulty patients face in accessing healthcare information despite rapid technology and treatment advancements.

Patients with SCAD and comorbid depression had greater rates of heart failure, cerebrovascular disease, acute kidney injury, and atrial fibrillation.

This interview at RAD 2025 highlights several notes on dose flexibility in atopic dermatitis, with commentary by presenter Raj Chovatiya, MD, PhD.

Lopez reviews findings from an analysis of ARISE-HF highlighting racial and ethnic differences in baseline characteristics and diabetic cardiomyopathy disease progression.

The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.

An analysis of the VALIANT trial provides insight into the benefits of pegcetacoplan in patients with C3G and IC-MPGN.